OPKO Health, Inc. (NASDAQ:OPK) to Post Q1 2025 Earnings of ($0.08) Per Share, HC Wainwright Forecasts

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of OPKO Health in a research note issued to investors on Wednesday, April 3rd. HC Wainwright analyst Y. Chen forecasts that the biotechnology company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for OPKO Health's Q3 2025 earnings at ($0.07) EPS.

Other equities analysts have also issued reports about the company. Piper Sandler reiterated an "overweight" rating and set a $5.00 price objective on shares of OPKO Health in a research report on Monday. StockNews.com downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Friday, March 1st. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $1.50 price objective on shares of OPKO Health in a research note on Monday.

OPKO Health Price Performance

Shares of OPK stock traded up $0.01 during trading on Thursday, hitting $1.36. The company had a trading volume of 6,128,363 shares, compared to its average volume of 15,008,521. The stock's 50-day moving average is $1.02 and its two-hundred day moving average is $1.26. The stock has a market capitalization of $947.91 million, a price-to-earnings ratio of -5.44 and a beta of 1.82. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. OPKO Health has a 52 week low of $0.85 and a 52 week high of $2.24.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). The firm had revenue of $181.90 million for the quarter, compared to analysts' expectations of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of OPKO Health by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company's stock worth $60,024,000 after acquiring an additional 428,520 shares during the last quarter. State Street Corp increased its position in OPKO Health by 56.7% in the first quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company's stock worth $95,250,000 after buying an additional 10,014,088 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of OPKO Health by 3.9% during the 2nd quarter. Geode Capital Management LLC now owns 8,742,614 shares of the biotechnology company's stock valued at $18,971,000 after buying an additional 331,968 shares in the last quarter. Millennium Management LLC grew its stake in shares of OPKO Health by 318.6% during the 2nd quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company's stock valued at $18,698,000 after acquiring an additional 5,624,866 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of OPKO Health by 73.2% in the first quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company's stock worth $24,717,000 after purchasing an additional 3,037,320 shares in the last quarter. Institutional investors own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm's stock in a transaction on Monday, March 18th. The stock was acquired at an average cost of $0.87 per share, with a total value of $435,000.00. Following the completion of the acquisition, the chief executive officer now owns 210,968,225 shares of the company's stock, valued at $183,542,355.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the stock in a transaction dated Monday, March 18th. The shares were purchased at an average cost of $0.87 per share, with a total value of $435,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,968,225 shares in the company, valued at approximately $183,542,355.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard M. Krasno acquired 30,000 shares of OPKO Health stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the acquisition, the director now directly owns 103,333 shares in the company, valued at approximately $102,299.67. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 8,993,015 shares of company stock valued at $8,479,069. Insiders own 47.26% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.